(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) presented Phase 1a clinical data for TTX-MC138, an investigational RNA-based therapy targeting metastatic cancers, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.